Mcn 5707 is a serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) designated for the treatment of depression. It was developed by Bruce Maryanoff of McNeil (now Johnson & Johnson) in the 1980s.
Binding affinities Binding affinities (Ki) are:
As can be seen, most of the activity resides in a single optical antipode (or enantiomer). Hence, there is a good eudysmic ratio.
SAR For related agents, see: JNJ-7925476, McN-4612, McN-5292, McN-5558, McN5652, and McN-5908. Other examples of drugs with ortho-chlorophenyl rings include:
Ketamine Clofedanol Clortermine Tulobuterol Disobutamide Bidisomide
References


